211 related articles for article (PubMed ID: 37897633)
1. SARS-CoV-2 Spike Protein S1 Domain Accelerates α-Synuclein Phosphorylation and Aggregation in Cellular Models of Synucleinopathy.
Wang J; Dai L; Deng M; Xiao T; Zhang Z; Zhang Z
Mol Neurobiol; 2024 Apr; 61(4):2446-2458. PubMed ID: 37897633
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro.
Wu Z; Zhang X; Huang Z; Ma K
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328814
[TBL] [Abstract][Full Text] [Related]
3. The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein.
Iravanpour F; Farrokhi MR; Jafarinia M; Oliaee RT
Hum Cell; 2024 Jan; 37(1):1-8. PubMed ID: 37735344
[TBL] [Abstract][Full Text] [Related]
4. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Spike Protein 1 Causes Aggregation of α-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin.
Chang MH; Park JH; Lee HK; Choi JY; Koh YH
Biomedicines; 2024 May; 12(6):. PubMed ID: 38927430
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward.
Bellomo G; De Luca CMG; Paoletti FP; Gaetani L; Moda F; Parnetti L
Neurology; 2022 Aug; 99(5):195-205. PubMed ID: 35914941
[TBL] [Abstract][Full Text] [Related]
7. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.
Conte C
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281186
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro.
Zilio G; Masato A; Sandre M; Caregnato A; Moret F; Maciola AK; Antonini A; Brucale M; Cendron L; Plotegher N; Bubacco L
ACS Chem Neurosci; 2024 Jan; 15(2):215-221. PubMed ID: 38131609
[TBL] [Abstract][Full Text] [Related]
9. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
10. Tau accelerates α-synuclein aggregation and spreading in Parkinson's disease.
Pan L; Li C; Meng L; Tian Y; He M; Yuan X; Zhang G; Zhang Z; Xiong J; Chen G; Zhang Z
Brain; 2022 Oct; 145(10):3454-3471. PubMed ID: 35552614
[TBL] [Abstract][Full Text] [Related]
11. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
12. Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents.
Sato H; Kato T; Arawaka S
Mol Neurobiol; 2015 Aug; 52(1):226-35. PubMed ID: 25143237
[TBL] [Abstract][Full Text] [Related]
13. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
14. Novel naturally occurring autoantibodies attenuate α-synuclein pathology in a mouse model of Parkinson's disease.
Li Y; Wang T; Meng L; Jin L; Liu C; Liang Y; Ren L; Liu Y; Liu Y; Liu S; Li T; Liang Y; Chen X; Zhang Z
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12860. PubMed ID: 36331758
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
16. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
17. Protein-protein interactions regulating α-synuclein pathology.
Wang J; Dai L; Chen S; Zhang Z; Fang X; Zhang Z
Trends Neurosci; 2024 Mar; 47(3):209-226. PubMed ID: 38355325
[TBL] [Abstract][Full Text] [Related]
18. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
19. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
20. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
